Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 9/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83699 | 1.00 | CA2 (0.50) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL90052 | 1.00 | CA2 (0.50) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL464290 | 0.93 | CTSK (0.45) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL30673406 | 0.86 | CA1 (0.46) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL206502 | 0.86 | CA1 (0.44) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL873787 | 0.86 | CA1 (0.44) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL873398 | 0.86 | CA1 (0.44) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL23722683 | 0.84 | CA1 (0.43) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL3805811 | 0.84 | CTSK (0.44) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL21746358 | 0.84 | CA1 (0.43) | CA2CA1CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115873034-B | Semi-active phosphoramide ligand and preparation method thereof | 上海毕臣生化科技有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-117624280-B | GATA transcription factor protein degradation targeting complex compound, and preparation method and application thereof | 斯达时代药业(苏州)有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-117624280-A | GATA transcription factor protein degradation targeting complex compound, and preparation method and application thereof | 南京师范大学 | 2024-03-01 | — | — | CN | claimed |
| CN-114907231-B | Indene chiral spiro fluorescent compound, and preparation method and application thereof | 杭州师范大学 | 2024-02-23 | — | — | CN | claimed |
| CN-117186004-A | Synthesis method of axial chiral biaryl quinoline nitroxide compound | 河南师范大学 | 2023-12-08 | — | — | CN | claimed |
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| CN-115873034-A | Semi-active phosphamide ligand and preparation method thereof | 上海毕臣生化科技有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-115611881-A | Method for synthesizing novel VHL ligand 4-F-VH032 | 复旦大学 | 2023-01-17 | — | — | CN | claimed |
| CN-115385984-A | Peptide-like derivative, preparation method and application | 北京科翔中升医药科技有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115108937-A | Synthesis method of alpha-azidoketone containing three-level stereocenter | 常州大学 | 2022-09-27 | — | — | CN | claimed |
| CN-114907231-A | Indene chiral spiro fluorescent compound and preparation method and application thereof | 杭州师范大学 | 2022-08-16 | — | — | CN | claimed |
| CN-114478627-A | Allylation monophosphine ligand and preparation method thereof | 湖北大学 | 2022-05-13 | — | — | CN | claimed |
| EP-2423187-A1 | PROCESS FOR PRODUCTION OF N-ALKOXYCARBONYL-tert-LEUCINES | Kaneka Corporation (JP) | 2012-02-29 | — | — | EP | claimed |
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2026-05-28 | — | — | US | disclosed |
| CN-122059930-A | Cdc25 phosphatase degradation agent based on quinoline dione skeleton, and preparation method and application thereof | 山东大学 | 2026-05-19 | — | — | CN | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-0615969-A1 | 2,4-Diamino-3-hydroxycarboxylic acid derivatives | SANDOZ LTD. (CH) | 1994-09-21 | — | — | EP | disclosed |
| US-5338726-A | Hypotensive agents, antiulcer agents | ABBOTT LABORATORIES (US) | 1994-08-16 | — | — | US | disclosed |
| WO-1993020099-A2 | CCK AND/OR GASTRIN RECEPTOR LIGANDS | FERRING B.V. (NL) | 1993-10-14 | — | — | WO | disclosed |
| WO-1992013545-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | PTPN6, PTPN1, PTPN11 | CA2 634/4885CA1 1860/4885CA7 825/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | CA2 2413/4885CA1 2045/4885CA7 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.